What is this study investigating about total hip arthroplasty?

This study is evaluating whether a blood vessel-sparing surgical technique during anterior approach total hip arthroplasty changes clinical outcomes compared to the standard vessel ligation method. Researchers want to see if sparing certain blood vessels reduces muscle tenderness and improves patient-reported hip function. The study is conducted by Ziekenhuis Oost-Limburg with careful monitoring of surgical results and patient health.

Who may be eligible for this total hip arthroplasty clinical trial?

Adults aged 18 years or older scheduled for total hip arthroplasty by specific surgeons may be eligible. Both males and females can participate. People with neurological problems, prior surgery on the same hip, or certain hip deformities are not eligible. Please review eligibility criteria for more details.

Is there any cost to participate in this total hip arthroplasty clinical trial?

Study-related care, including the surgical procedure and all trial visits, is provided at no cost. However, personal travel and other expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any additional costs.

Actively Recruiting

Phase Not Applicable

Age: 18Years +

All Genders

ID06308965

Does Vessel-sparing Surgery in Anterior Approach Total Hip Arthroplasty Change Clinical Outcome?

Led by Ziekenhuis Oost-Limburg · Updated on 2024-11-15

300

Participants Needed

Research Sites

104 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are investigating whether a blood vessel-sparing surgical technique during direct anterior approach total hip arthroplasty (DAA THA) can improve clinical outcomes compared to the standard vessel ligation method. This trial focuses on patients undergoing hip replacement and aims to determine if sparing the lateral femoral circumflex artery reduces muscle tenderness and the incidence of tensor fascia lata (TFL) tendinopathy. The study is a prospective, randomized, blinded clinical trial conducted at a single center, with a planned duration of at least three years or until enrollment exceeds the target sample size by 50% (100 patients). Participants will be randomly assigned to one of two groups: one undergoing the vessel-sparing surgical procedure and the other receiving the standard vessel ligation technique. The feasibility of the vessel-sparing technique, including whether it can be successfully performed in about 60% of patients, will be observed. The trial will compare clinical outcomes such as the incidence of TFL tendinopathy, patient-reported hip function scores, and component placement on X-rays one year after surgery. During the study, patients will be monitored through follow-up assessments at one year post-surgery, including evaluations of TFL tendinopathy incidence, modified Harris Hip Score, Hip And Groin Outcome Score, Forgotten Joint Score, and Hip disability and Osteoarthritis Outcome Score. X-ray imaging will assess the placement of hip components. The success of the vessel-sparing technique will be assessed at the end of surgery. The entire participant involvement is designed to collect comprehensive data on surgical outcomes and patient-reported measures to understand the impact of the vessel-sparing approach.